Back to Journals » ImmunoTargets and Therapy » Volume 10
![](https://www.dovepress.com/cr_data/cache/journal_image/138/cope/thumb_100_1000_100.jpg)
ImmunoTargets and Therapy
ISSN: 2253-1556
- View all (178)
- Volume 13, 2024 (23)
- Volume 12, 2023 (14)
- Volume 11, 2022 (6)
- Volume 10, 2021 (30)
- Volume 9, 2020 (27)
- Volume 8, 2019 (5)
- Volume 7, 2018 (10)
- Volume 6, 2017 (8)
- Volume 5, 2016 (8)
- Volume 4, 2015 (17)
- Volume 3, 2014 (14)
- Volume 2, 2013 (13)
- Volume 1, 2012 (3)
Archive: Volume 10, 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Pathophysiology of Non-IgE-Mediated Food Allergy
Zhang S, Sicherer S, Berin MC, Agyemang A
ImmunoTargets and Therapy 2021, 10:431-446
Published Date: 29 December 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Understanding and Managing Severe Asthma in the Context of COVID-19
Kong-Cardoso B, Ribeiro A, Aguiar R, Pité H, Morais-Almeida M
ImmunoTargets and Therapy 2021, 10:419-430
Published Date: 11 December 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Role of IL-17 Cytokines in Psoriasis
Mosca M, Hong J, Hadeler E, Hakimi M, Liao W, Bhutani T
ImmunoTargets and Therapy 2021, 10:409-418
Published Date: 24 November 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies
Karmakar S, Pal P, Lal G
ImmunoTargets and Therapy 2021, 10:387-407
Published Date: 1 November 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Role of Complement in Synaptic Pruning and Neurodegeneration
Gomez-Arboledas A, Acharya MM, Tenner AJ
ImmunoTargets and Therapy 2021, 10:373-386
Published Date: 24 September 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Immunotherapy of Multiple Myeloma: Promise and Challenges
Abramson HN
ImmunoTargets and Therapy 2021, 10:343-371
Published Date: 9 September 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
Arneson LC, Carroll KJ, Ruderman EM
ImmunoTargets and Therapy 2021, 10:333-342
Published Date: 28 August 2021
![Autoimmune neuropathies have started attracting much more attention recently because of improved diagnostics and the appearance of novel therapeutics. More education on this group of diseases is urgently needed not only for neurologists but for the wider group of practicing physicians and researchers.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20
Levy M, Mealy MA
ImmunoTargets and Therapy 2021, 10:325-331
Published Date: 20 August 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
Bughda R, Dimou P, D'Souza RR, Klampatsa A
ImmunoTargets and Therapy 2021, 10:313-323
Published Date: 5 August 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Alopecia Areata: An Autoimmune Disease of Multiple Players
Suchonwanit P, Kositkuljorn C, Pomsoong C
ImmunoTargets and Therapy 2021, 10:299-312
Published Date: 29 July 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Contribution of Toll-Like Receptors and the NLRP3 Inflammasome in Rheumatoid Arthritis Pathophysiology
Unterberger S, Davies KA, Rambhatla SB, Sacre S
ImmunoTargets and Therapy 2021, 10:285-298
Published Date: 28 July 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Complement Inhibition and COVID-19: The Story so Far
Fodil S, Annane D
ImmunoTargets and Therapy 2021, 10:273-284
Published Date: 26 July 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cannabis and Autoimmunity: Possible Mechanisms of Action
Giorgi V, Marotto D, Batticciotto A, Atzeni F, Bongiovanni S, Sarzi-Puttini P
ImmunoTargets and Therapy 2021, 10:261-271
Published Date: 21 July 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Cancer-Immunity Cycle in Multiple Myeloma
Casey M, Nakamura K
ImmunoTargets and Therapy 2021, 10:247-260
Published Date: 16 July 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era
Kasarello K, Mirowska-Guzel D
ImmunoTargets and Therapy 2021, 10:237-246
Published Date: 7 July 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Targeting CD22 for the Treatment of B-Cell Malignancies
Shah NN, Sokol L
ImmunoTargets and Therapy 2021, 10:225-236
Published Date: 6 July 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Next-Generation Allergen-Specific Immunotherapy for Japanese Cedar Pollinosis Using Molecular Approaches
Takaiwa F
ImmunoTargets and Therapy 2021, 10:213-224
Published Date: 2 July 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
CD38-Directed Therapies for Management of Multiple Myeloma
Hashmi H, Husnain M, Khan A, Usmani SZ
ImmunoTargets and Therapy 2021, 10:201-211
Published Date: 29 June 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
VISTA: A Promising Target for Cancer Immunotherapy?
Tagliamento M, Agostinetto E, Borea R, Brandão M, Poggio F, Addeo A, Lambertini M
ImmunoTargets and Therapy 2021, 10:185-200
Published Date: 22 June 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Memory Generation and Re-Activation in Food Allergy
Koenig JFE, Bruton K, Phelps A, Grydziuszko E, Jiménez-Saiz R, Jordana M
ImmunoTargets and Therapy 2021, 10:171-184
Published Date: 9 June 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
NHS-IL12, a Tumor-Targeting Immunocytokine
Greiner JW, Morillon II YM, Schlom J
ImmunoTargets and Therapy 2021, 10:155-169
Published Date: 27 May 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis
Atzeni F, Carriero A, Boccassini L, D'Angelo S
ImmunoTargets and Therapy 2021, 10:141-153
Published Date: 3 May 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
Xu N, Tse B, Yang L, Tang TCY, Haber M, Micklethwaite K, Dolnikov A
ImmunoTargets and Therapy 2021, 10:123-140
Published Date: 28 April 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
TNFR2: Role in Cancer Immunology and Immunotherapy
Yang Y, Islam MS, Hu Y, Chen X
ImmunoTargets and Therapy 2021, 10:103-122
Published Date: 21 April 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?
Held F, Klein AK, Berthele A
ImmunoTargets and Therapy 2021, 10:87-101
Published Date: 19 March 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches
Hasan A, Al-Ozairi E, Al-Baqsumi Z, Ahmad R, Al-Mulla F
ImmunoTargets and Therapy 2021, 10:63-85
Published Date: 9 March 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Soluble IL-7Rα/sCD127 in Health, Disease, and Its Potential Role as a Therapeutic Agent
Barros PO, Berthoud TK, Aloufi N, Angel JB
ImmunoTargets and Therapy 2021, 10:47-62
Published Date: 8 March 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Anti-IgE for the Treatment of Chronic Urticaria
Wedi B, Traidl S
ImmunoTargets and Therapy 2021, 10:27-45
Published Date: 17 February 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
Passiglia F, Reale ML, Cetoretta V, Novello S
ImmunoTargets and Therapy 2021, 10:9-26
Published Date: 5 February 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Current Insights into Immunotherapy Approaches for Food Allergy
Macdougall JD, Burks AW, Kim EH
ImmunoTargets and Therapy 2021, 10:1-8
Published Date: 27 January 2021